Invivyd Inc. (IVVD)

NASDAQ: IVVD · Real-Time Price · USD

0.61

-0.02 (-3.21%)

At close: May 01, 2025, 3:59 PM

0.61

0.97%

After-hours: May 01, 2025, 06:00 PM EDT

-3.21% (1D)

Bid	0.6
Market Cap	72.86M
Revenue (ttm)	25.38M
Net Income (ttm)	-169.93M
EPS (ttm)	-1.43
PE Ratio (ttm)	-0.42
Forward PE	0.73
Analyst	Buy

Ask	0.62
Volume	449,047
Avg. Volume (20D)	15,237,042
Open	0.65
Previous Close	0.63
Day's Range	0.60 - 0.63
52-Week Range	0.35 - 2.74
Beta	0.41

About IVVD

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with A...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 6, 2021

Employees 99

Stock Exchange NASDAQ

Ticker Symbol IVVD

Website https://adagiotx.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for IVVD stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 1381.73% from the latest price.

Stock Forecasts

Next Earnings Release

Invivyd Inc. is scheduled to release its earnings on May 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+2.58%

Invivyd shares are trading higher after the compan... Unlock content with Pro Subscription

2 months ago

-29.94%

Invivyd shares are trading lower after the company announced the FDA has declined its request to expand its existing emergency use authorization of PEMGARDA.

News

1 month ago · zacks.com

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago.

2 months ago · zacks.com

5 Stocks That More Than Doubled Halfway Through Q1

We highlight five stocks from different sectors that more than doubled halfway through the first quarter.

2 months ago · benzinga.com

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

On Monday, the FDA declined Invivyd, Inc.'s IVVD request to expand the existing emergency use authorization (EUA) for pre-exposure prophylaxis of COVID-19 EUA for Pemgarda (pemivibart) for mild-to-mod...

2 months ago · seekingalpha.com

I See The Bull Case For Invivyd, But I'm Not Married To It

Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue i...